Azacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Austrian Azacitidine Registry of the AGMT Study Group

We recently published a clinically-meaningful improvement in median overall survival (OS) for patients with acute myeloid leukaemia (AML), >30% bone marrow (BM) blasts and white blood cell (WBC) count ≤15 G/L, treated with front-line azacitidine versus conventional care regimens within a phase 3...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Int J Mol Sci
Päätekijät: Pleyer, Lisa, Döhner, Hartmut, Dombret, Hervé, Seymour, John F., Schuh, Andre C., Beach, CL, Swern, Arlene S., Burgstaller, Sonja, Stauder, Reinhard, Girschikofsky, Michael, Sill, Heinz, Schlick, Konstantin, Thaler, Josef, Halter, Britta, Machherndl Spandl, Sigrid, Zebisch, Armin, Pichler, Angelika, Pfeilstöcker, Michael, Autzinger, Eva M., Lang, Alois, Geissler, Klaus, Voskova, Daniela, Sperr, Wolfgang R., Hojas, Sabine, Rogulj, Inga M., Andel, Johannes, Greil, Richard
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: MDPI 2017
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5343949/
https://ncbi.nlm.nih.gov/pubmed/28212292
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijms18020415
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia